Biodel (BIOD) Tops Q3 View By 2c
More News related to BIOD
- Biodel Reports Protective Effects of VIAject(TM) Insulin on Microvascular Function in Patients with Type 2 Diabetes
- Biodel Receives Notice of Allowance for Insulin Patent Claims in Europe
- Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
- Biodel Announces Timing of FDA Discussions on VIAject(TM)
- Oppenheimer Initiates Coverage on Biodel (BIOD)
More News related to Earnings
- Friedman Billings Starts Aircastle (AYR) at Underperform
- Friedman Billings Starts Netflix (NFLX) at Market Perform
- Credit Suisse Starts 3PAR (PAR) at Neutral
- Credit Suisse Starts Netezza (NZ) at Neutral
- FBR Starts Amazon.com (AMZN) at Market Perform
Biodel (Nasdaq: BIOD) reports a Q3 loss of $0.43, 2 cents better than the analyst estimate of ($0.45).
Biodel, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of treatments for endocrine disorders, such as diabetes and osteoporosis.
Related Categories
EarningsStocks Mentioned
-0.31Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
